Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): Overview and structural insights

There is considerable interest in the development of an inhibitor of aldo-keto reductase (AKR) 1C3 (type 5 17β-hydroxysteroid dehydrogenase and prostaglandin F synthase) as a potential therapeutic for both hormone-dependent and hormone-independent cancers. AKR1C3 catalyzes the reduction of 4-androstene-3,17-dione to testosterone and estrone to 17β-estradiol in target tissues, which will promote the proliferation of hormone dependent prostate and breast cancers, respectively. AKR1C3 also catalyzes the reduction of prostaglandin (PG) H(2) to PGF(2α) and PGD(2) to 9α,11β-PGF(2), which will limit the formation of anti-proliferative prostaglandins, including 15-deoxy-Δ(12,14)-PGJ(2), and contribute to proliferative signaling. AKR1C3 is overexpressed in a wide variety of cancers, including breast and prostate cancer. An inhibitor of AKR1C3 should not inhibit the closely related isoforms AKR1C1 and AKR1C2, as they are involved in other key steroid hormone biotransformations in target tissues. Several structural leads have been explored as inhibitors of AKR1C3, including non-steroidal anti-inflammatory drugs, steroid hormone analogues, flavonoids, cyclopentanes, and benzodiazepines. Inspection of the available crystal structures of AKR1C3 with multiple ligands bound, along with the crystal structures of the other AKR1C isoforms, provides a structural basis for the rational design of isoform specific inhibitors of AKR1C3. We find that there are subpockets involved in ligand binding that are considerably different in AKR1C3 relative to the closely related AKR1C1 or AKR1C2 isoforms. These pockets can be used to further improve the binding affinity and selectivity of the currently available AKR1C3 inhibitors. Article from the special issue on Targeted Inhibitors.

[1]  S. Rudnick,et al.  Development of Nonsteroidal Anti-Inflammatory Drug Analogs and Steroid Carboxylates Selective for Human Aldo-Keto Reductase Isoforms: Potential Antineoplastic Agents That Work Independently of Cyclooxygenase Isozymes , 2005, Molecular Pharmacology.

[2]  N. Palackal,et al.  Crystal structure of human type III 3alpha-hydroxysteroid dehydrogenase/bile acid binding protein complexed with NADP(+) and ursodeoxycholate. , 2001, Biochemistry.

[3]  Seon-Hwa Lee,et al.  Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer , 2010, The Journal of Steroid Biochemistry and Molecular Biology.

[4]  T. Penning,et al.  Human cytosolic 3alpha-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3beta-hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action. , 2003, The Journal of biological chemistry.

[5]  Taro Yamada,et al.  Prostaglandin F2alpha formation from prostaglandin H2 by prostaglandin F synthase (PGFS): crystal structure of PGFS containing bimatoprost. , 2006, Biochemistry.

[6]  Sheng-Xiang Lin,et al.  Crystal structures of the multispecific 17beta-hydroxysteroid dehydrogenase type 5: critical androgen regulation in human peripheral tissues. , 2004, Molecular endocrinology.

[7]  D. Poirier,et al.  Steroidal lactones as inhibitors of 17beta-hydroxysteroid dehydrogenase type 5: chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities. , 2009, European journal of medicinal chemistry.

[8]  T. Penning,et al.  Human hydroxysteroid dehydrogenases and pre-receptor regulation: Insights into inhibitor design and evaluation , 2011, The Journal of Steroid Biochemistry and Molecular Biology.

[9]  M. Neuhouser.  Review: Dietary Flavonoids and Cancer Risk: Evidence From Human Population Studies , 2004, Nutrition and cancer.

[10]  S. Andersson,et al.  Estrogen and progesterone metabolism in the cervix during pregnancy and parturition. , 2008, The Journal of clinical endocrinology and metabolism.

[11]  R. DuBois,et al.  Cyclooxygenase, NSAIDs, and colorectal cancer , 1996, Journal of Gastroenterology.

[12]  M. Nishizawa,et al.  cDNA cloning, expression and characterization of human prostaglandin F synthase 1 , 1999 .

[13]  S. Grösch,et al.  Evidence of COX-2 independent induction of apoptosis and cell cycle block in human colon carcinoma cells after S- or R-ibuprofen treatment. , 2006, European journal of pharmacology.

[14]  S. Gobec,et al.  Cinnamic acids as new inhibitors of 17β-hydroxysteroid dehydrogenase type 5 (AKR1C3) , 2006, Molecular and Cellular Endocrinology.

[15]  T. Penning,et al.  Inhibition of a major NAD(P)-linked oxidoreductase from rat liver cytosol by steroidal and nonsteroidal anti-inflammatory agents and by prostaglandins. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[16]  R. Breitling,et al.  Human 17beta-hydroxysteroid dehydrogenase type 5 is inhibited by dietary flavonoids. , 2002, Advances in experimental medicine and biology.

[17]  D. Peehl,et al.  Identification of the Major Oxidative 3α-Hydroxysteroid Dehydrogenase in Human Prostate That Converts 5α-Androstane-3α,17β-diol to 5α-Dihydrotestosterone: A Potential Therapeutic Target for Androgen-Dependent Disease , 2006 .

[18]  T. Penning,et al.  Molecular docking simulations of steroid substrates into human cytosolic hydroxysteroid dehydrogenases (AKR1C1 and AKR1C2): Insights into positional and stereochemical preferences , 2006, Steroids.

[19]  Richard A. Anderson,et al.  A positive feedback loop that regulates cyclooxygenase-2 expression and prostaglandin F2alpha synthesis via the F-series-prostanoid receptor and extracellular signal-regulated kinase 1/2 signaling pathway. , 2005, Endocrinology.

[20]  J. A. Murray,et al.  Combined Bezafibrate and Medroxyprogesterone Acetate: Potential Novel Therapy for Acute Myeloid Leukaemia , 2009, PloS one.

[21]  J. Scher,et al.  The Anti-Inflammatory Effects of Prostaglandins , 2009, Journal of Investigative Medicine.

[22]  D. Poirier.  Contribution to the development of inhibitors of 17β-hydroxysteroid dehydrogenase types 1 and 7: Key tools for studying and treating estrogen-dependent diseases , 2011, The Journal of Steroid Biochemistry and Molecular Biology.

[23]  Heidi D Nelson,et al.  Postmenopausal hormone replacement therapy: scientific review. , 2002, JAMA.

[24]  R. Phipps,et al.  The Peroxisome Proliferator-Activated Receptor γ (PPARγ) Ligands 15-Deoxy-Δ12,14-Prostaglandin J2 and Ciglitazone Induce Human B Lymphocyte and B Cell Lymphoma Apoptosis by PPARγ-Independent Mechanisms1 , 2006, The Journal of Immunology.

[25]  J. Lehmann,et al.  A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation , 1995, Cell.

[26]  T. Penning,et al.  Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. , 2009, Chemico-biological interactions.

[27]  S. Ito,et al.  Synthesis of prostaglandin F ethanolamide by prostaglandin F synthase and identification of Bimatoprost as a potent inhibitor of the enzyme: new enzyme assay method using LC/ESI/MS. , 2004, Archives of biochemistry and biophysics.

[28]  Rachelle S. Singleton,et al.  The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. , 2010, Cancer research.

[29]  T. Penning,et al.  Tibolone Metabolism in Human Liver Is Catalyzed by 3α/3β-Hydroxysteroid Dehydrogenase Activities of the Four Isoforms of the Aldo-Keto Reductase (AKR)1C Subfamily , 2006, Journal of Pharmacology and Experimental Therapeutics.

[30]  Fernand Labrie,et al.  Human 20α–Hydroxysteroid Dehydrogenase: Crystallographic and Site-directed Mutagenesis Studies Lead to the Identification of an Alternative Binding Site for C21-steroids , 2003 .

[31]  H. Shiraishi,et al.  Identification of a principal mRNA species for human 3alpha-hydroxysteroid dehydrogenase isoform (AKR1C3) that exhibits high prostaglandin D2 11-ketoreductase activity. , 1998, Journal of biochemistry.

[32]  M. J. Bennett,et al.  Steroid recognition and regulation of hormone action: crystal structure of testosterone and NADP+ bound to 3 alpha-hydroxysteroid/dihydrodiol dehydrogenase. , 1997, Structure.

[33]  O. Stål,et al.  17β-Hydroxysteroid Dehydrogenase 14 Affects Estradiol Levels in Breast Cancer Cells and Is a Prognostic Marker in Estrogen Receptor–Positive Breast Cancer , 2006 .

[34]  G. Jenster,et al.  Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. , 2010, Cancer research.

[35]  P. Nelson,et al.  Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. , 2008, Cancer research.

[36]  Michael E. Burczynski,et al.  Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1–AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones , 2000 .

[37]  C. Bunce,et al.  Crystal Structures of Prostaglandin D2 11-Ketoreductase (AKR1C3) in Complex with the Nonsteroidal Anti-Inflammatory Drugs Flufenamic Acid and Indomethacin , 2004, Cancer Research.

[38]  A. Hara,et al.  Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. , 2002, Biological & pharmaceutical bulletin.

[39]  R. Auchus,et al.  Deoxycorticosterone inactivation by AKR1C3 in human mineralocorticoid target tissues , 2006, Molecular and Cellular Endocrinology.

[40]  S. Gobec,et al.  New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3. , 2009, European journal of medicinal chemistry.

[41]  D. Tindall,et al.  Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor γ ligand, 15-deoxy-Δ12,14-prostaglandin J2 , 2000 .

[42]  M. Leroy,et al.  Differential Expression of the Enzymatic System Controlling Synthesis, Metabolism, and Transport of PGF2 Alpha in Human Fetal Membranes1 , 2010, Biology of reproduction.

[43]  T. Penning,et al.  Pre-receptor regulation of the androgen receptor , 2008, Molecular and Cellular Endocrinology.

[44]  T. Golub,et al.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. , 2006, Cancer research.

[45]  New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3. , 2009, European journal of medicinal chemistry.

[46]  Sheng-Xiang Lin,et al.  Structure-based Inhibitor Design for an Enzyme That Binds Different Steroids , 2007, Journal of Biological Chemistry.

[47]  D. Welch,et al.  Modulation of mammary cancer cell migration by 15-deoxy-delta(12,14)-prostaglandin J(2): implications for anti-metastatic therapy. , 2010, The Biochemical journal.

[48]  T. Rižner,et al.  Aberrant pre-receptor regulation of estrogen and progesterone action in endometrial cancer , 2009, Molecular and Cellular Endocrinology.

[49]  Trevor M. Penning,et al.  Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3α-hydroxysteroid dehydrogenase/type 5 17β-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate , 2004, Steroids.

[50]  J. Perman.  Methane and colorectal cancer , 1984 .

[51]  T. Shiraishi,et al.  15-Deoxy-Δ12,14-prostaglandin J2 induces death receptor 5 expression through mRNA stabilization independently of PPARγ and potentiates TRAIL-induced apoptosis , 2006, Molecular Cancer Therapeutics.

[52]  B. Husen,et al.  Disturbed estrogen and progesterone action in ovarian endometriosis , 2009, Molecular and Cellular Endocrinology.

[53]  O. El-Kabbani,et al.  Selective and potent inhibitors of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1) that metabolizes neurosteroids derived from progesterone. , 2003, Chemico-biological interactions.

[54]  E. Maser,et al.  AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids. , 2009, Chemico-biological interactions.

[55]  P. Soucy,et al.  Characteristics of a Highly Labile Human Type 5 17β-Hydroxysteroid Dehydrogenase1. , 1999, Endocrinology.

[56]  Taro Yamada,et al.  Crystal structure of human prostaglandin F synthase (AKR1C3). , 2004, Biochemistry.

[57]  K. Groom,et al.  Prostaglandin inhibitors in preterm labour. , 2003, Best practice & research. Clinical obstetrics & gynaecology.

[58]  P. Nelson,et al.  Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. , 2007, Cancer research.

[59]  M. Lazar,et al.  Prostaglandins Promote and Block Adipogenesis through Opposing Effects on Peroxisome Proliferator-activated Receptor γ* , 1998, The Journal of Biological Chemistry.

[60]  R. Hayden,et al.  AKR1C isoforms represent a novel cellular target for jasmonates alongside their mitochondrial-mediated effects. , 2009, Cancer research.

[61]  Takashi Suzuki,et al.  In situ androgen producing enzymes in human prostate cancer. , 2005, Endocrine-related cancer.

[62]  T. Penning,et al.  An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies. , 2008, Biochemical pharmacology.

[63]  D. Poirier.  Inhibitors of 17β-Hydroxysteroid Dehydrogenases , 2003 .